New hope for stubborn muscle weakness? tiny study tests targeted therapy
NCT ID NCT07499323
First seen Apr 20, 2026 · Last updated May 15, 2026 · Updated 5 times
Summary
This early study tests a drug called talquetamab in just 2 people with refractory generalized myasthenia gravis, a chronic autoimmune disease causing muscle weakness. The drug aims to destroy the immune cells that attack the body. The goal is to see if it can control the disease and improve daily living, but it is not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS (MG) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.